-Swedish Moberg Derma Q2 loss widens due to bigger costs.
NORDIC BUSINESS REPORT-August 12, 2011--Swedish Moberg Derma Q2 loss widens due to bigger costs(C)2011 M2 COMMUNICATIONS http://www.m2.com
12 August 2011 - Swedish pharma company Moberg Derma AB (STO:MOB) said today its second-quarter net loss widened to SEK9.6m from SEK8m a year earlier as a big increase in revenue was outweighed by even higher costs.
Revenue amounted to SEK8m in April-June 2011, up from SEK219,000. However, costs of goods sold surged to SEK4.3m from SEK60,000. Research and development (R&D) costs grew to SEK7.1m from SEK4.9m, and expenses for marketing and administration also increased.
As a result, the operating loss widened to SEK9.7m from SEK8m.
This was Moberg Derma's first quarter as a listed company. The firm floated on the Nasdaq OMX Nordic exchange in Stockholm on 26 May after a new share issue that brought net proceeds of SEK69.2m.
In the first half of 2011, Moberg Derma saw its net loss expand to SEK16.2m from SEK12.7m a year earlier although revenue surged to SEK13.5m from SEK823,000.
(EUR1 = SEK9.3)
((Comments on this story may be sent to email@example.com)).END.PUB430>PDAugust 12, 2011>JNNORDIC BUSINESS REPORT.PRICEDATENOT APPLICABLE.DAY
|Printer friendly Cite/link Email Feedback|
|Publication:||Nordic Business Report|
|Article Type:||Financial report|
|Date:||Aug 12, 2011|
|Previous Article:||-Pronova BioPharma plans to start phase I trials with lipid-derived drug.|
|Next Article:||-Brokers lower price targets on Novozymes after Q2.|